Sora is an analyst on the Stewardship Funds and is responsible for screening investments, engaging with portfolio companies, and reporting on the Funds’ ESG performance.
Experience and qualifications
Prior to joining Aviva Investors, she worked on CDP’s Supply Chain programme where she advised companies on their supplier engagement strategies, Scope 3 emissions and science-based targets. Previous to this, Sora worked at Merck and led the company’s work on the Access to Medicine Index in 2016. She started her sustainability journey in research roles for the UN and the World Business Council for Sustainable Development (WBCSD).
Sora holds a BA in Politics and French from King’s College London and an MA in International Relations from the Graduate Institute Geneva, and is currently pursuing an MSc in Carbon Management at the University of Edinburgh.
Associate Director Responsible Investment
Impact Analyst - Social Pillar Lead
Senior Corporate Governance Analyst
Senior Manager, Sustainable Finance Centre for Excellence
Chief Responsible Investment Officer
Senior Corporate Governance Analyst
Senior GRI Analyst, Climate Specialist
Senior ESG analyst
Senior ESG Analyst & Earth Pillar Lead
ESG Operations Manager
Global Head of ESG and Strategic Partnerships
Global Head of ESG Investments
ESG Associate Director, Real Assets
Head of ESG – Sovereign
You might also be interested in
The AIQ Podcast: Taking stock of nature risk
15 Jul 2022
The idea that human actions are bringing natural systems close to breakdown, threatening livelihoods and financial stability, is making asset managers think harder about nature risk and the environmental dependencies in investee companies.
Investing in a just transition to net zero: A Q&A with Nick Robins
30 Jun 2022
Reaching net zero by 2050 will require significant injections of capital. But it is also an opportunity to rethink social relationships, as Professor Nick Robins explains.
Supply chains, painkillers and gene editing: ESG risks in pharma
29 Jun 2022
Reflecting on ESG risks in the pharmaceutical industry, Sora Utzinger discusses supply chains and counterfeit medicines, access to painkillers, and the ethics of gene editing.
What does the data say? Biodiversity loss: From horror to hope
24 Jun 2022
In this month’s instalment of our visual series on topical themes, we explore the world of biodiversity.
ESG investing: Lasting lessons from Russia’s war on Ukraine
23 Jun 2022
Russia’s invasion of Ukraine has led to ESG receiving widespread flak. While much of the criticism is unjustified, the episode underlines how many issues related to ESG are complex and involve trade-offs. Investment approaches may need fine tuning, especially if the geopolitical landscape continues to change so rapidly.
Antimicrobial resistance: Q&A with Dame Sally Davies
10 Jun 2022
Resistance to antibiotics is already killing millions. Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance, spoke to AIQ on the latest developments to counter antimicrobial resistance Antimicrobial Resistance (AMR) in the UK and globally.
The AIQ Podcast: Investing towards a new social contract
9 Jun 2022
As life returns to some form of normality, governments are free to move their focus from COVID-19 to left-behind communities and delivering a just transition. This is important to secure long-term economic outcomes, but also comes with investment opportunities and risks.
Deep water: Ten threats to marine ecosystems
8 Jun 2022
Our air, weather, food, the health of diverse marine life and millions of jobs all depend on the ocean. But we have not done well as custodians of marine ecosystems. Here, we set out ten ways where human actions threaten the health of an essential environment.
Levelling up: Investing towards a new social contract
17 May 2022
As we learn to live with COVID-19, focus is returning to delivering a just transition. This is important to secure long-term investment outcomes, but also presents direct opportunities.
Life force: Why nature matters
12 May 2022
Growing awareness that natural systems are stressed or even close to breakdown is prompting asset managers to look closely at nature-based risks and investee companies to understand their environmental impacts and dependencies.
Back to nature: Why we must act now on the biodiversity crisis
31 Mar 2022
In an age of mass extinctions, policymakers, businesses and financial institutions are beginning to acknowledge the risks associated with biodiversity loss, along with the opportunities that arise from nature-positive solutions.
Power to the people: The moral and investment case for human rights
30 Mar 2022
Healthy and happy employees, consumers, and communities are all critical ingredients in a company’s long-term success. Investors have a key responsibility in ensuring the rights of these groups are respected.
Now for the hard part…..The challenge of delivering net zero
29 Mar 2022
More than one fifth of the world’s largest listed companies have committed to net-zero targets, but few have detailed roadmaps to get there. Mirza Baig considers the challenges for investors managing transition pathways.
Change diets, not the planet: The link between food and sustainability
29 Mar 2022
We explore how shifting diets can help create a more sustainable world.
Tough gig: How to improve the platform economy
28 Mar 2022
Companies operating in the gig economy have been subject to industrial action and legal challenges. Workers say they are being denied basic rights; platforms reply this is the price of flexibility. But there is a viable middle-ground which can be beneficial for all, including investors.
Energy in focus: Part 2: The pivot to green
28 Mar 2022
How will the surge in the prices of oil, gas and coal impact the transition to low or zero carbon sources of fuel? In the second part of our Q&A on the energy sector, experts from our credit, equities and ESG teams contemplate the challenges and opportunities in the pivot to green.